VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $99,096,453 | +5.1% | 1,943,830 | +3.0% | 0.04% | +10.5% |
Q2 2023 | $94,292,014 | +2917.0% | 1,888,106 | +2164.2% | 0.04% | +3700.0% |
Q1 2023 | $3,125,382 | -11.5% | 83,388 | +13.2% | 0.00% | -50.0% |
Q4 2022 | $3,533,340 | +225.7% | 73,688 | +63.0% | 0.00% | +100.0% |
Q3 2022 | $1,085,000 | +10.3% | 45,200 | 0.0% | 0.00% | – |
Q2 2022 | $984,000 | -7.4% | 45,200 | +2.7% | 0.00% | – |
Q1 2022 | $1,063,000 | +20.4% | 44,000 | +18.6% | 0.00% | – |
Q4 2021 | $883,000 | -6.2% | 37,100 | 0.0% | 0.00% | – |
Q3 2021 | $941,000 | +38.4% | 37,100 | +22.8% | 0.00% | – |
Q2 2021 | $680,000 | +53.8% | 30,200 | +34.8% | 0.00% | – |
Q1 2021 | $442,000 | -36.9% | 22,400 | -15.2% | 0.00% | – |
Q4 2020 | $701,000 | -46.2% | 26,400 | 0.0% | 0.00% | -100.0% |
Q3 2020 | $1,304,000 | – | 26,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |